Oncology Decision Support in Ovarian Cancer: Artificial Intelligence Based Pathomics to Identify Platinum Resistant Epithelial Ovarian Cancer
February 3, 2023
Targeting circadian clock proteins for novel therapeutics to treat Acute Myeloid Leukemia
July 18, 2023

Therapeutic Targeting of Hdm2/HdmX E3 Ligase in CRC

The interaction between the RING domains of Hdm2/HdmX E3 ligase is an effective therapeutic target for cancer treatment and prevention. We have already developed a bioactive cyclotide, MCo-52-2, able to inactivate Hdm2/HdmX E3 ligase activity in vitro and in vivo. The main goal of this proposal is to continue the development of this cyclotide as a single compound therapeutic agent using several mouse models of CRC.